Harmony Biosciences beats Q2 estimates with $1.28 EPS, $261M revenue

Harmony Biosciences reported Q2 EPS of $1.28, beating the $1.02 consensus estimate, on revenue of $261.3 million.

The results, released Aug. 4, mark the commercial-stage biopharma's latest beat on both the top and bottom lines, according to the company's earnings release.

Revenue of $261.3 million came in about $7.9 million, or 3.1 percent, above the $253.4 million analysts had projected. Adjusted EPS of $1.28 topped the $1.02 consensus by 26 percent. The company did not disclose full-year guidance in the release.

The beat points to sustained demand for Wakix, Harmony's narcolepsy treatment, which anchors a CNS-focused portfolio that competes with Jazz Pharmaceuticals' Xywav in the sleep-disorder market. Investors will watch the earnings call for pipeline updates and any revision to the commercial outlook for the second half of 2026.

The Q2 performance extends Harmony's pattern of exceeding Street forecasts as Wakix continues to drive the bulk of revenue. The company has not yet disclosed segment-level detail or updated guidance for the full year, leaving the trajectory of its core franchise dependent on the product's commercial execution.

Harmony's results come as the narcolepsy category sees growing competition, with Jazz Pharmaceuticals and Axsome Therapeutics expanding their CNS offerings. The company's ability to hold share will hinge on the commercial performance of Wakix and progress across its pipeline, which includes candidates targeting other sleep and neurologic conditions.

The beat signals that Harmony's core franchise remains on solid footing heading into the second half of 2026. The next catalyst is the earnings call, where management is expected to address guidance and pipeline timing.

This article is for informational purposes only and does not constitute investment advice.